Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2020)

Monopar Therapeutics' Share-based Compensation history spans 4 years, with the latest figure at $331322.0 for Q4 2020.

  • For Q4 2020, Share-based Compensation rose 19.7% year-over-year to $331322.0; the TTM value through Dec 2020 reached $1.3 million, up 30.63%, while the annual FY2024 figure was $1.1 million, 39.89% down from the prior year.
  • Share-based Compensation for Q4 2020 was $331322.0 at Monopar Therapeutics, up from $283713.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $367358.0 in Q2 2020 and bottomed at $43926.0 in Q3 2017.
  • The 4-year median for Share-based Compensation is $233776.0 (2019), against an average of $211106.5.
  • The largest YoY upside for Share-based Compensation was 268.72% in 2018 against a maximum downside of 55.29% in 2018.
  • A 4-year view of Share-based Compensation shows it stood at $63189.0 in 2017, then surged by 268.72% to $232992.0 in 2018, then grew by 18.8% to $276805.0 in 2019, then increased by 19.7% to $331322.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Share-based Compensation are $331322.0 (Q4 2020), $283713.0 (Q3 2020), and $367358.0 (Q2 2020).